Diabetic Macular Edema | Treatment Algorithms | Claims Data Analysis | US | 2025
Diabetic macular edema (DME), a complication of diabetic retinopathy caused by persistently high blood sugar levels, can lead to vision loss if untreated. VEGF inhibitors such as Eylea, Lucentis, and off-label Avastin have traditionally been the first-line treatments, while the corticosteroid implants Ozurdex and Iluvien are generally reserved for later stages of therapy. Novartis’s Beovu has seen limited adoption in DME management, largely due to safety concerns. The treatment landscape expanded with the launch of Roche’s Vabysmo in 2022 and Regeneron’s Eylea HD in 2023, both addressing the need for longer dosing intervals. Competition further increased with the market entry of Lucentis biosimilars, offering similar efficacy at a significantly lower price to the brand.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed DME patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed DME patients?
- How has Vabysmo been integrated into the treatment algorithm, and what is its source of business?
- What percentage of newly diagnosed DME patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of DME patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
PRODUCT ENHANCEMENT
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
